MediLink Therapeutics
Next-generation ADC therapies for cancer
Suzhou, China · Founded 2020 · $120.0M raised
- Headquarters
- Suzhou
- Founded
- 2020
- Business Model
- B2B
- Website
- medilinkthera.com
- Total Funding
- $120.0M
- Last Round
- $70.0M Series BMar 2022
- Rounds
- 2
About
MediLink Therapeutics, founded July 8, 2020 in Suzhou, China, is an innovative drug development company specializing in antibody-drug conjugates (ADC) and related technologies. The company's proprietary TMALIN® (Tumor Microenvironment Activable Linker-payload) platform enables next-generation ADC therapeutics that combine the targeting precision of antibodies with the cytotoxic power of small molecules. MediLink has established subsidiaries in Shanghai, Boston, Hong Kong, and Singapore. Key partnerships include worldwide collaboration and license agreements with Roche and BioNTech. The company completed a $70M Series B in 2022 and its lead asset YL201 has received FDA Breakthrough Therapy Designation and Orphan Drug Designation.
Summary
MediLink Therapeutics is an Antibody Drug Conjugates company based in Suzhou, China, founded in 2020. It has raised $120.0M in total across 2 rounds, most recently a $70.0M Series B round in Mar 2022.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable...
Liquid biopsy cancer screening company integrating multi-cancer early detection into routine medi...
Pathos is an AI-enabled biotechnology company focused on re-engineering drug development.
Clinical-stage oncology company developing novel CAR-T cell therapies for hematological malignanc...